drugset / Trial / NCT00418054

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

NCT00418054

Phase 2 Completed 40 enrolled Romark Laboratories L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks with nitazoxanide monotherapy in the treatment of chronic hepatitis C.

Timeline

Start
2005-12
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified
Background Peginterferon alfa-2b Protein / enzyme biologic